Table 8.

Analysis of pro- and anti-inflammatory markers (PRD; defined as 25% decline in eGFR)

Pro- and Anti-Inflammatory MarkersPatients without PRD, d0Patients with PRD, d0P ValuePatients without PRD, d3Patients with PRD, d3P Value
MIF, median (Q1, Q3), pg/ml15,019.2 (10,189.2, 44,648.4)16,675.2 (8085.6, 36,628.8)0.9211,283.6 (5988.6, 23,681.1)6588.0 (3412.8, 12,800.4)0.04
IL-6, median (Q1, Q3), pg/ml1151.4 (354.1, 1794.9)943.9 (210.8, 2175.2)0.56282.7 (102.1, 552.1)253.6 (100.2, 699.0)0.91
IL-8, median (Q1, Q3), pg/ml313.6 (123.5, 571.2)220.5 (88.6, 443.5)0.2273.3 (30.9, 129.2)51.4 (16.0, 100.5)0.19
IL-10, median (Q1, Q3), pg/ml44.6 (20.8, 153.0)39.8 (14.9, 101.3)0.3422.2 (9.6, 48.6)15.3 (9.2, 28.1)0.47
IL-18, median (Q1, Q3), pg/ml727.0 (343.7, 1153.7)565.5 (267.8, 1374.8)0.46777.3 (350.9, 1849.6)381.2 (241.9, 747.5)<0.01
TNFR-1, median (Q1, Q3), pg/ml1600.3 (1221.1, 2104.9)1838.6 (1035.0, 2521.0)0.521447.8 (951.1, 2021.1)2058.4 (945.4, 2898.8)0.21
TNFR-2, median (Q1, Q3), pg/ml22,630.0 (14,873.8, 27,055.0)18,577.6 (11,624.6, 27,280.0)0.1820,880.0 (11,916.3, 29,420.0)20,200.0 (13,090.0, 39,715.0)0.48
  • Patients who died within 1 year are excluded; n=39 patients with PRD at 1 year. d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.